Arno Therapeutics to Present Three Posters Supporting Onapristone Development at ASCO Annual Meeting 2015

FLEMINGTON, N.J., April 29, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that three posters supporting the ongoing clinical development program for lead compound onapristone will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL.

Arno will present findings from its Phase I study of onapristone in women with progesterone receptor (PR)-expressing tumors, including efficacy and biomarker results. Arno will also provide updates on its Phase II trial of onapristone in patients with metastatic or recurrent endometrioid tumors that express the activated progesterone receptor (APR), and its separate Phase I/II clinical trial of onapristone in patients with castration-resistant prostate cancer whose tumors are PR positive – both of which are currently enrolling patients.

The three accepted abstracts will be presented during two poster sessions, both on Saturday, May 30; additional details include:

  • Abstract TPS5616 / Poster 168b: Phase 2 clinical study of onapristone (ONA) in patients (pts) with uterine endometrioid adenocarcinoma (EC) expressing the activated progesterone receptor (APRpos)

First / Presenting Author: Jacques Bonneterre, MD, PhD, Centre Oscar Lambret
Poster Session: Gynecologic Cancer
Date, Time: Saturday, May 30; 1:15 PM - 4:45 PM
Location: S Hall A

  • Abstract 5593 / Poster 151: Onapristone (ONA) in progesterone receptor (PR)-expressing tumors: efficacy and biomarker results of a dose-escalation phase 1 study

First / Presenting Author: Paul H. Cottu, MD, MSc, Institut Curie
Poster Session: Gynecologic Cancer
Date, Time: Saturday, May 30; 1:15 PM - 4:45 PM
Location: S Hall A

  • Abstract 5051 / Poster 44: Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC) - PK, safety and PR testing results from the dose escalation cohort

First / Presenting Author: Anuradha Jayaram, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust
Poster Session: Genitourinary (Prostate) Cancer
Date, Time: Saturday, May 30; 1:15 PM - 4:45 PM
Location: S Hall A

Onapristone is an oral, anti-progestin hormone blocker that has been shown in previous Phase II clinical trials (not sponsored by Arno) to exhibit anti-tumor activity in patients with breast cancer. In pre-clinical testing, onapristone has been shown to block the activation of PR, which is believed to be a mechanism that inhibits the growth of APR driven breast, endometrial and other, primarily gynecological tumors. APR has the potential to function as a biomarker of anti-progestin activity, as detected by a companion diagnostic currently under development with Arno's partner, Leica Biosystems.

About Arno Therapeutics

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening diseases. Arno has exclusive worldwide rights to develop and market three innovative product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors, as well as infectious diseases. For more information about the company, please visit www.arnothera.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the timing, progress and anticipated results of the clinical development of onapristone, including the ability to identify and treat those patients most likely to benefit from onapristone, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. Arno may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements made here. Various important factors could cause actual results or events to differ materially from these forward-looking statements. Such factors include, among others, risks that the results of clinical trials will not support claims or beliefs concerning the effectiveness of onapristone or any other product candidates, the ability to successfully develop a diagnostic to identify APR tumors, the ability to finance the development of Arno's product candidates, regulatory risks, and reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2014. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

CONTACT: The Ruth Group Lee Roth (investors) lroth@theruthgroup.com (646) 536-7012 Kirsten Thomas (media) kthomas@theruthgroup.com (646) 536-7014 Arno Therapeutics Lawrence Kenyon lk@arnothera.com (862) 703-7171

Source:Arno Therapeutics Inc.